2-[3-(4-hydroxy-1-methylpiperidin-4-yl)-1H-indol-5-yl]-N-methylethanesulfonamide | 1123177-86-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[3-(4-hydroxy-1-methylpiperidin-4-yl)-1H-indol-5-yl]-N-methylethanesulfonamide
• CAS: 1123177-86-5
• 化学式: C₁₇H₂₅N₃O₃S
• 分子量: 351.47
• InChiKey: IEYUSYKVZUTQIX-UHFFFAOYSA-N

物化性质

• 沸点：
  593.9±60.0 °C(Predicted)
• 密度：
  1.307±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.17
• 重原子数：
  24.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  85.43
• 氢给体数：
  3.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 N-甲基-1H-吲哚-5-乙基磺酰胺 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以54%的产率得到2-[3-(4-hydroxy-1-methylpiperidin-4-yl)-1H-indol-5-yl]-N-methylethanesulfonamide
  参考文献：
  名称：

  An Investigation into the Formation of Impurity B during the Optimization of Naratriptan Hydrochloride

  摘要：

  During the process development of naratriptan hydrochloride we have made an unusual observation about the enhanced levels of intermediate 3 as an impurity (impurity B) in the final stage. Detailed investigation has led to the conclusion that impurity B is not only a carried over but also formed via acid catalyzed dehydration of yet another process related impurity. The present work details a report of the journey towards the development of an efficient process for the commercial production of naratriptan hydrochloride substantially free from the impurity B.

  DOI：

  10.1021/op800286f

文献信息

• An Investigation into the Formation of Impurity B during the Optimization of Naratriptan Hydrochloride
  作者：U. Sampath Kumar、V. Ravi Sankar、S. Bharani Kumar、M. Pandi Prabhu、S. Mahender Rao

  DOI：10.1021/op800286f

  日期：2009.5.15

  During the process development of naratriptan hydrochloride we have made an unusual observation about the enhanced levels of intermediate 3 as an impurity (impurity B) in the final stage. Detailed investigation has led to the conclusion that impurity B is not only a carried over but also formed via acid catalyzed dehydration of yet another process related impurity. The present work details a report of the journey towards the development of an efficient process for the commercial production of naratriptan hydrochloride substantially free from the impurity B.